From: Abnormal glycosylation in glioma: related changes in biology, biomarkers and targeted therapy
Pathway | Enzyme or protein | Category | Specific effects | Reference |
---|---|---|---|---|
RTK related pathway | GnT-III | N-acetylglucosaminyltransfease | Influencing EGF binding and receptor autophosphorylation | [106] |
GnT-V | Influencing PLCγ-PKC pathway | [111] | ||
GALNT2 | N-acetylgalactosaminyltransferase | Influencing PI3K/Akt/mTOR | [114] | |
FUT8 | Fucosyltransferase | Influencing LCA binding to MET and EGFR | [96] | |
MUC4 | Mucin | Regulating EGFR expression | [9] | |
GOLPH3 | Golgi phosphoprotein | Decreasing EGFR proliferation signaling activity | [116] | |
TGF-β pathway | ST3GAL1 | Sialytransferase | Indirectly controlling FoxM1 protein degradation by the APC/C-Cdh1 complex | [117] |
MAPK pathway | Hsc70 | Heat shock protein | Decreasing the levels of β4GalT5 downstream signaling proteins P-ERK1, P-JNK1 and P-Akt. | [119] |
Advanced Glycation End Products | Glycotoxins | Activating tyrosine kinase and RAS related pathways, inducing the activation of p38 MAPK | [168] |